[ATP生物发光法肿瘤化疗药敏检测与卵巢癌临床疗效的相关性]
[Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
作者信息
Tian Hai-mei, Shi Xiao-yan, Fu Jun, Chao Dong-yan, Zhang Kai, Wu Ling-ying, Wang Jin-wan, Zhang Wei
机构信息
Tumor Marker Research Center, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhonghua Zhong Liu Za Zhi. 2005 May;27(5):296-8.
OBJECTIVE
To determine the correlation between results of ATP bioluminescence tumor chemosensitivity assay (ATP-TCA) of human ovarian cancer specimens in vitro and clinical chemo-therapeutic responses of patients.
METHODS
Thirty-four freshly taken ovarian cancer specimens (28 cases) and ascites (6 cases) and 9 chemotherapeutic drugs were tested in vitro for cancer chemosensitivity by ATP-TCA.
RESULTS
Among the 34 ovarian cancer cases, the efficacy of ATP-TCA is 94.0%, the sensitivity, the specificity, the positive and negative predicting values, and an overall predicting value in vitro and vivo were 90.0%, 91.7%, 94.7%, 84.6% and 90.6%, respectively.
CONCLUSION
The results of ATP-TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for individual-based chemotherapy of cancers.
目的
确定人卵巢癌标本体外ATP生物发光肿瘤化疗药敏试验（ATP-TCA）结果与患者临床化疗反应之间的相关性。
方法
采用ATP-TCA对34份新鲜采集的卵巢癌标本（28例）和腹水标本（6例）以及9种化疗药物进行体外癌症化疗药敏试验。
结果
34例卵巢癌病例中，ATP-TCA的有效率为94.0%，体外和体内的敏感性、特异性、阳性和阴性预测值以及总体预测值分别为90.0%、91.7%、94.7%、84.6%和90.6%。
结论
ATP-TCA试验结果与临床治疗反应具有良好的相关性。该试验可能是癌症个体化化疗的一种重要且有用的方法。
Zotero 插件